Timothy Voorhees, MD, MSCR
@tvoorheesmd.bsky.social
Assistant Professor @OSUCCC_James | #Lymphoma | Previously @UNC_Lineberger & @OSUWexMed | Proud Dad/Husband | Tweets & Opinions Are My Own, Not Medical Advice
Reposted by Timothy Voorhees, MD, MSCR
Timothy Voorhees, MD @tvoorheesmd.bsky.social published "Outcomes in patients with classic #Hodgkinlymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers" in @BloodCancerJnl.
🔗https://pubmed.ncbi.nlm.nih.gov/40140364/
🔗https://pubmed.ncbi.nlm.nih.gov/40140364/
April 8, 2025 at 5:07 PM
Timothy Voorhees, MD @tvoorheesmd.bsky.social published "Outcomes in patients with classic #Hodgkinlymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers" in @BloodCancerJnl.
🔗https://pubmed.ncbi.nlm.nih.gov/40140364/
🔗https://pubmed.ncbi.nlm.nih.gov/40140364/
Important data for CD20 bispecific therapy - no significant effect of prior bendamustine exposure.
Prior benda in EPCORE NHL-1 @LymphClinician #ASH24:
- 27% of trial pts w/ prior benda
- no diff in ORR (59.5 vs 62.7%) w or w/o benda
- also no diff PFS (4.4 mo both), CRS or ICANS
- no effect on cytotoxic T cells
Now seen in multiple series: https://buff.ly/3AOI470 #lymsm
- 27% of trial pts w/ prior benda
- no diff in ORR (59.5 vs 62.7%) w or w/o benda
- also no diff PFS (4.4 mo both), CRS or ICANS
- no effect on cytotoxic T cells
Now seen in multiple series: https://buff.ly/3AOI470 #lymsm
November 19, 2024 at 1:47 PM
Important data for CD20 bispecific therapy - no significant effect of prior bendamustine exposure.